Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma

pharmatimesAugust 06, 2021

Tag: BMS , Istodax , PTCL

PharmaSources Customer Service